Dataset Name:		NGA10151
Dataset Description: Final	
Item Status: 	
Study Name: 	WHO Novel Coronavirus (nCoV) Database - NIGERIA-10151
Protocol ID: 	Novel Coronavirus (WHO_nCoV)  - NGA-10151
Date: 	2021-Sep-21
Subjects: 	8
Study Event Definitions	3
Study Event Definition 1	1_ADMISSION	E1
CRF1	COVADM3 - V1.3	C1
Study Event Definition 2	2_FOLLOWUP	E2
CRF3	COVFUP2 - V1.3	C3
Study Event Definition 3	3_OUTCOME	E3
CRF5	COVDIV3 - V1.2	C5










Study Subject ID	Protocol ID	 admpro_E1_C1 	 admsit_E1_C1 	 admcou_E1_C1 	 admpar_E1_C1 	 adm01_E1_C1 	 adm03_E1_C1 	 adm04_E1_C1 	 adm05_E1_C1 	 adm06_E1_C1 	 adm07_E1_C1 	 adm09_1_E1_C1 	 adm10_E1_C1 	 adm11_E1_C1 	 adm12_E1_C1 	 adm13_E1_C1 	 adm14_E1_C1 	 adm15_E1_C1 	 adm16_E1_C1 	 adm17_E1_C1 	 adm18_1_E1_C1 	 adm18_2_E1_C1 	 adm19_E1_C1 	 adm20_E1_C1 	 adm21_E1_C1 	 adm21s1_E1_C1 	 adm21s2_E1_C1 	 adm22_E1_C1 	 adm23_E1_C1 	 adm27_E1_C1 	 adm28_E1_C1 	 adm29_E1_C1 	 adm30_E1_C1 	 adm31_E1_C1 	 adm32_E1_C1 	 adm33_E1_C1 	 adm34_E1_C1 	 adm35_E1_C1 	 adm36_E1_C1 	 adm37_E1_C1 	 adm38_E1_C1 	 adm39_E1_C1 	 adm40_E1_C1 	 adm41_E1_C1 	 adm42_E1_C1 	 adm43_E1_C1 	 adm44_E1_C1 	 adm44s_E1_C1 	 adm45_E1_C1 	 adm46_E1_C1 	 adm47_E1_C1 	 adm48_E1_C1 	 adm48s1_E1_C1 	 adm49_E1_C1 	 adm48s2_E1_C1 	 adm50_E1_C1 	 adm51_E1_C1 	 adm52_E1_C1 	 adm53_E1_C1 	 adm54_E1_C1 	 adm55_E1_C1 	 adm56_E1_C1 	 adm57_E1_C1 	 adm58_E1_C1 	 adm59_E1_C1 	 adm60_E1_C1 	 adm61_E1_C1 	 adm62_E1_C1 	 adm63_E1_C1 	 adm64_E1_C1 	 adm65_E1_C1 	 adm66_E1_C1 	 adm67_E1_C1 	 adm68_E1_C1 	 adm69_E1_C1 	 adm70_E1_C1 	 adm71_E1_C1 	 adm72_E1_C1 	 adm73_E1_C1 	 adm73s1_E1_C1 	 adm73s2_E1_C1 	 adm74_E1_C1 	 adm75_E1_C1 	 adm76_E1_C1 	 adm77_E1_C1 	 adm78_E1_C1 	 adm79_E1_C1 	 adm80_E1_C1 	 adm81_E1_C1 	 adm82_E1_C1 	 adm83_E1_C1 	 adm84_E1_C1 	 adm84s1_E1_C1 	 adm84s2_E1_C1 	 adm84s3_E1_C1 	 adm85_E1_C1 	 adm86_E1_C1 	 adm87_E1_C1 	 adm88_E1_C1 	 adm89_E1_C1 	 adm32a_E1_C1 	 adm69a_E1_C1 	 adm69b_E1_C1 	 adm75s_E1_C1 	 adm90__E1_C1 	 adm90s__E1_C1 	 adm91_1_E1_C1 	 adm91s_1_E1_C1 	 adm92__E1_C1 	 adm92s__E1_C1 	 adm93__E1_C1 	 adm93s__E1_C1 	 adm94s__E1_C1 	 adm95__E1_C1 	 adm95s__E1_C1 	 adm96__E1_C1 	 adm96s__E1_C1 	 adm97s__E1_C1 	 adm98s__E1_C1 	 adm99s__E1_C1 	 adm100s__E1_C1 	 adm101s__E1_C1 	 adm103s__E1_C1 	 adm104__E1_C1 	 adm104s__E1_C1 	 adm105s__E1_C1 	 adm108__E1_C1 	 adm108s__E1_C1 	 adm107s__E1_C1 	 adm106s__E1_C1 	 adm109s__E1_C1 	 adm110__E1_C1 	 adm110s__E1_C1 	 adm111s__E1_C1 	 adm112s__E1_C1 	 adm113s__E1_C1 	 fuppro_E2_1_C3 	 fupsit_E2_1_C3 	 fupcou_E2_1_C3 	 fuppar_E2_1_C3 	 fup01_E2_1_C3 	 fup02_E2_1_C3 	 fup03_E2_1_C3 	 fup04_E2_1_C3 	 fup05_1_E2_1_C3 	 fup05_2_E2_1_C3 	 fup06_E2_1_C3 	 fup07_E2_1_C3 	 fup08_E2_1_C3 	 fup09_E2_1_C3 	 fup09s1_E2_1_C3 	 fup09s2_E2_1_C3 	 fup10_E2_1_C3 	 fup11_E2_1_C3 	 fup10s1_E2_1_C3 	 fup12_E2_1_C3 	 fup13_E2_1_C3 	 fup14_E2_1_C3 	 fup15_E2_1_C3 	 fup16_E2_1_C3 	 fup17_E2_1_C3 	 fup18_E2_1_C3 	 fup19_E2_1_C3 	 fup20_E2_1_C3 	 fup21_E2_1_C3 	 fup22_E2_1_C3 	 fup47_E2_1_C3 	 fup48_E2_1_C3 	 fup49_E2_1_C3 	 fup49s1_E2_1_C3 	 fup49s2_E2_1_C3 	 fup50_E2_1_C3 	 fup51_E2_1_C3 	 fup52_E2_1_C3 	 fup53_E2_1_C3 	 fup54_E2_1_C3 	 fup55_E2_1_C3 	 fup56_E2_1_C3 	 fup57_E2_1_C3 	 fup58_E2_1_C3 	 fup59_E2_1_C3 	 fup59s1_E2_1_C3 	 fup60_E2_1_C3 	 fup60s1_E2_1_C3 	 fup60s2_E2_1_C3 	 fup60s3_E2_1_C3 	 fup61_E2_1_C3 	 fup62_E2_1_C3 	 fup63_E2_1_C3 	 fup64_E2_1_C3 	 fup65_E2_1_C3 	 fup66_E2_1_C3 	 fup23__E2_1_C3 	 fup23s__E2_1_C3 	 fup24__E2_1_C3 	 fup24s__E2_1_C3 	 fup25__E2_1_C3 	 fup25s__E2_1_C3 	 fup26__E2_1_C3 	 fup26s__E2_1_C3 	 fup27s__E2_1_C3 	 fup28__E2_1_C3 	 fup28s__E2_1_C3 	 fup29__E2_1_C3 	 fup29s__E2_1_C3 	 fup30s__E2_1_C3 	 fup31s__E2_1_C3 	 fup32s__E2_1_C3 	 fup33s__E2_1_C3 	 fup34s__E2_1_C3 	 fup36s__E2_1_C3 	 fup37s__E2_1_C3 	 fup38s__E2_1_C3 	 fup41s__E2_1_C3 	 fup40s__E2_1_C3 	 fup39s__E2_1_C3 	 fup42s__E2_1_C3 	 fup43__E2_1_C3 	 fup43s__E2_1_C3 	 fup44s__E2_1_C3 	 fup45s__E2_1_C3 	 fup46s__E2_1_C3 	 fup51s_E2_1_C3 	 fuppro_E2_2_C3 	 fupsit_E2_2_C3 	 fupcou_E2_2_C3 	 fuppar_E2_2_C3 	 fup01_E2_2_C3 	 fup02_E2_2_C3 	 fup03_E2_2_C3 	 fup04_E2_2_C3 	 fup05_1_E2_2_C3 	 fup05_2_E2_2_C3 	 fup06_E2_2_C3 	 fup07_E2_2_C3 	 fup08_E2_2_C3 	 fup09_E2_2_C3 	 fup09s1_E2_2_C3 	 fup09s2_E2_2_C3 	 fup10_E2_2_C3 	 fup11_E2_2_C3 	 fup10s1_E2_2_C3 	 fup12_E2_2_C3 	 fup13_E2_2_C3 	 fup14_E2_2_C3 	 fup15_E2_2_C3 	 fup16_E2_2_C3 	 fup17_E2_2_C3 	 fup18_E2_2_C3 	 fup19_E2_2_C3 	 fup20_E2_2_C3 	 fup21_E2_2_C3 	 fup22_E2_2_C3 	 fup22s_E2_2_C3 	 fup47_E2_2_C3 	 fup48_E2_2_C3 	 fup49_E2_2_C3 	 fup49s1_E2_2_C3 	 fup49s2_E2_2_C3 	 fup50_E2_2_C3 	 fup51_E2_2_C3 	 fup52_E2_2_C3 	 fup53_E2_2_C3 	 fup54_E2_2_C3 	 fup55_E2_2_C3 	 fup56_E2_2_C3 	 fup57_E2_2_C3 	 fup58_E2_2_C3 	 fup59_E2_2_C3 	 fup60_E2_2_C3 	 fup60s1_E2_2_C3 	 fup60s2_E2_2_C3 	 fup60s3_E2_2_C3 	 fup61_E2_2_C3 	 fup62_E2_2_C3 	 fup63_E2_2_C3 	 fup64_E2_2_C3 	 fup65_E2_2_C3 	 fup66_E2_2_C3 	 fup23__E2_2_C3 	 fup23s__E2_2_C3 	 fup24__E2_2_C3 	 fup24s__E2_2_C3 	 fup25__E2_2_C3 	 fup25s__E2_2_C3 	 fup26__E2_2_C3 	 fup26s__E2_2_C3 	 fup27s__E2_2_C3 	 fup28__E2_2_C3 	 fup28s__E2_2_C3 	 fup29__E2_2_C3 	 fup29s__E2_2_C3 	 fup30s__E2_2_C3 	 fup31s__E2_2_C3 	 fup32s__E2_2_C3 	 fup33s__E2_2_C3 	 fup34s__E2_2_C3 	 fup36s__E2_2_C3 	 fup37s__E2_2_C3 	 fup38s__E2_2_C3 	 fup41s__E2_2_C3 	 fup40s__E2_2_C3 	 fup39s__E2_2_C3 	 fup42s__E2_2_C3 	 fup43__E2_2_C3 	 fup43s__E2_2_C3 	 fup44s__E2_2_C3 	 fup45s__E2_2_C3 	 fup46s__E2_2_C3 	 fup51s_E2_2_C3 	 fuppro_E2_3_C3 	 fupsit_E2_3_C3 	 fupcou_E2_3_C3 	 fuppar_E2_3_C3 	 fup01_E2_3_C3 	 fup02_E2_3_C3 	 fup03_E2_3_C3 	 fup05_1_E2_3_C3 	 fup05_2_E2_3_C3 	 fup06_E2_3_C3 	 fup07_E2_3_C3 	 fup08_E2_3_C3 	 fup09_E2_3_C3 	 fup09s1_E2_3_C3 	 fup10_E2_3_C3 	 fup11_E2_3_C3 	 fup10s1_E2_3_C3 	 fup12_E2_3_C3 	 fup13_E2_3_C3 	 fup14_E2_3_C3 	 fup15_E2_3_C3 	 fup16_E2_3_C3 	 fup17_E2_3_C3 	 fup18_E2_3_C3 	 fup19_E2_3_C3 	 fup20_E2_3_C3 	 fup21_E2_3_C3 	 fup22_E2_3_C3 	 fup47_E2_3_C3 	 fup48_E2_3_C3 	 fup49_E2_3_C3 	 fup49s1_E2_3_C3 	 fup49s2_E2_3_C3 	 fup50_E2_3_C3 	 fup51_E2_3_C3 	 fup52_E2_3_C3 	 fup53_E2_3_C3 	 fup54_E2_3_C3 	 fup55_E2_3_C3 	 fup56_E2_3_C3 	 fup57_E2_3_C3 	 fup58_E2_3_C3 	 fup59_E2_3_C3 	 fup60_E2_3_C3 	 fup61_E2_3_C3 	 fup62_E2_3_C3 	 fup63_E2_3_C3 	 fup64_E2_3_C3 	 fup65_E2_3_C3 	 fup66_E2_3_C3 	 fup23s__E2_3_C3 	 fup24s__E2_3_C3 	 fup25s__E2_3_C3 	 fup26s__E2_3_C3 	 fup27s__E2_3_C3 	 fup28s__E2_3_C3 	 fup29s__E2_3_C3 	 fup30s__E2_3_C3 	 fup31s__E2_3_C3 	 fup32s__E2_3_C3 	 fup33s__E2_3_C3 	 fup34s__E2_3_C3 	 fup36s__E2_3_C3 	 fup37s__E2_3_C3 	 fup38s__E2_3_C3 	 fup41s__E2_3_C3 	 fup40s__E2_3_C3 	 fup39s__E2_3_C3 	 fup42s__E2_3_C3 	 fup43s__E2_3_C3 	 fup44s__E2_3_C3 	 fup45s__E2_3_C3 	 fup46s__E2_3_C3 	 dispro_E3_C5 	 dissit_E3_C5 	 discou_E3_C5 	 diapar_E3_C5 	 dis01_E3_C5 	 dis01s_E3_C5 	 dis02_E3_C5 	 dis03_E3_C5 	 dis04_E3_C5 	 dis04s1_E3_C5 	 dis05_E3_C5 	 dis06_E3_C5 	 dis07_E3_C5 	 dis08_E3_C5 	 dis09_E3_C5 	 dis10_E3_C5 	 dis11_E3_C5 	 dis12_E3_C5 	 dis13_E3_C5 	 dis14_E3_C5 	 dis15_E3_C5 	 dis16_E3_C5 	 dis17_E3_C5 	 dis18_E3_C5 	 dis19_E3_C5 	 dis20_E3_C5 	 dis21_E3_C5 	 dis22_E3_C5 	 dis23_E3_C5 	 dis24_E3_C5 	 dis25_E3_C5 	 dis26_E3_C5 	 dis27_E3_C5 	 dis28_E3_C5 	 dis29_E3_C5 	 dis30_E3_C5 	 dis31_E3_C5 	 dis31s1_E3_C5 	 dis31s2_E3_C5 	 dis32_E3_C5 	 dis32s_E3_C5 	 dis33_E3_C5 	 dis34_E3_C5 	 dis35_E3_C5 	 dis36_E3_C5 	 dis37_E3_C5 	 dis38_E3_C5 	 dis38s1_E3_C5 	 dis38s2_E3_C5 	 dis38s5_E3_C5 	 dis39_E3_C5 	 dis39s1_E3_C5 	 dis39s2_E3_C5 	 dis39s3_E3_C5 	 dis39s4_E3_C5 	 dis40_E3_C5 	 dis40s_E3_C5 	 dis41_E3_C5 	 dis42_E3_C5 	 dis43_E3_C5 	 dis44_E3_C5 	 dis45_E3_C5 	 dis46_E3_C5 	 dis47_E3_C5 	 dis48_E3_C5 	 dis27a_E3_C5 	 dis27b_E3_C5 	 dis37a_E3_C5 	 dis37as_E3_C5 	
88888-0001	Novel Coronavirus (WHO_nCoV)  - NGA-10151	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0001	2020-12-31	1	1	2	1	2	52	1	2	2	2020-12-24	2020-12-31	38.9	110	44			2	2	51	2	2	6	2	2	2	1	2	2	2	2	2	2	2	2	3	2	4	2	2	2	1		1	3	1	1	1	2	2	2	2	3	2	2	2	1	2	2	3	2	3	2	3	2	1	2	1	2	2	2	2	2	1	6	Chloroquine	2	1	2	2	2	2	2	2	2	1	1	4	2	4	1	1	2	2	1	2	2	2	Ciprofloxacin		1	107	2		1	141	1	1	3.7	1		1	1	1	1	1	1	1	344	1	1	485	1	1	1	1	13.1	1	1	2	1	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0001	2021-01-01	36.5	89	44			2	2	7	31	2	2	2	2		2	2	2	1	1	1	2	3	2	3	3	2	1	1	6	Chloroquine	2	1	2	2	2	2	2	2	2	2		1	4	2	4	1	1	2	2	2	2		1		1		1		1	1		1		1	1	1	1	1	1	1	1	1	1	1	1	1		1	1	1	1	Ciproflaxacin																																																																																																																																																																	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0001	2		1	3	1	2	3	2	2	2	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		2	1	1	6	Chloroquine	1	Azithromycin	2	2	2	2	2	2				1	1	4	2	4	1	1	2	2	1	2	2	4	2021-01-01		2	2	2		
88888-0006	Novel Coronavirus (WHO_nCoV)  - NGA-10151	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0006	2021-01-08	2	1	2	1	2	51	2		2	2021-01-01	2021-02-08	37.8	81	36	127	91	2	2	96	1	1	15	2	2	1	1	2	2	2	2	2	2	2	2	2	2	4	2	2	2	4	Ivermectin	1	3	1	1	2	2	2	2	2	2	2	2	2	2	2	2	1	2	1	2	1	2	2	2	2	2	2	2	2	1	1	6	Ivermectin	2	2	2	2	2	2	2	2	2	2	2				2	2	2	2	2	2	2	2			1		1		1		1	1		1		1	1	1	1	1	1	1		1	1		1	1	1	1		1	1	1	1	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0006	2021-01-09	36.1	72	20	114	78	2	2	10	97	1	1	1	2	2	2	2	2	2	2	2	2	2	1	2	2	2	1	1	6	Ivermectin, Azithromycin	2	2	2	2	2	2	2	2	3	2		2				2	2	2	2	2	2		1		1		1		1	1		1		1	1	1	1	1	1	1	1	1	1	1	1	1		1	1	1	1		WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0006	2021-01-10	35.8	62	20	117	86	2	2	13	99	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	1	Epigastric pain	2	1	1	6	Ivermectin, Azithromycin	2	2	2	2	2	2	2	2	2	2	2				2	2	2	2	2	2		1		1		1		1	1		1		1	1	1	1	1	1	1	1	1	1	1	1	1		1	1	1	1		WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0006	2021-01-12	35.9	67	106	73	2	2	13	99	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	1	6	Ivermectin, Azithromycin	2	2	2	2	2	1	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0006	2		1	2	2		3	2	2	2	3	3	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	1	6	Ivermectin, Azithromycin	2		2	2	2	2	2	2				2					2		2	2	2	2	2	1	2021-01-17	3	2	2	2		
88888-0002	Novel Coronavirus (WHO_nCoV)  - NGA-10151	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0002	2021-01-02																																																																																																																																																																																																																																																																																																																																																																																																																																																															
88888-0016	Novel Coronavirus (WHO_nCoV)  - NGA-10151	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0016	2021-01-15	1	1	1	1	2	54	2	2	2	2021-01-08	2021-01-15	39	111	28	150	98	2	2	87	1	1	10	2	2	1	1	2	2	2	3	3	2	2	2	2	2	4	2	1	2	2		1	2	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	2	2	1	2			2	1	2	2	2	2	2	1	2	2	1				2	2	2	2	2	2	2	2	Azithromycin		1		1		1		1	1		1		1	1	1	1	1	1	1		1	1		1	1	1	1		1	1	1	1	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0016	2021-01-28	36.2	95	22	147	87	2	3	11	93	1	1	2	2		2	2	2	2	2	2	2	2	2	2	2	2	1	2			2	1	2	2	2	2	2	1	2	2		1	1	2	4	2	2	2	2	2	2	11.6	1	116	1	7620	1	135	1	1	3.5	1	278000	1	1	1	1	1	1	1	1	1	1	1	1	1	3.7	1	1	1	1	Augmentin, cefpodoxime																																																																																																																																																																	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0016	1	3	3										2	2	2	2	2	2	2	1	2	2	2	2	2	2	2	2	2	2	2	1	2			1	Azithromycin, cefpodoxime, Flagyl	2	2	2	2	2	2				1	9	1	2	4	2		2	2	2	2	2	1	2021-01-30	3	2	2	2		
88888-0015	Novel Coronavirus (WHO_nCoV)  - NGA-10151	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0015	2021-01-17	1	1	2	1	2	62	2	2	2	2021-01-06	2021-01-17	35.6	83	20	105	67	2	3	91	1	1	10	2	2	1	1		3	2	3	3	2	2	2	2	2	4	2	1	2	2		1	2	1	1	1	2	2	2	2	2	2	2	2	2	1	2	2	2	1	2	1	2	2	2	2	2	2	3	2	1	2			2	1	2	2	2	2	2	1	2	2	1				1	2	2	2	2	2	2	2	Azithromycin		1		2		1		1	1		1		1	1	1	1	1	1	1		1	1		1	1	1	1		1	1	1	1	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0015	2021-01-28	36.5	75	30	112	64	2	2	12	99	1	1	1	2	1	2	2	2	1	2	2	2	2	2	2	3	2	2				2	1	2	2	2	2	2	1	2	2		2			4	2	2			2	2	12.1	1	82	2	7270	1	131	1	1	4.4	1	682000	1	1	1	1	1	1	1	1	1	1	1	1	1	7.3	1	1	1	1	Azithromycin																																																																																																																																																																	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0015	3		3										2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	2			1	Azithromycin	2	2	2	2	2	2				1	8	1	2	4	2		2	2	2	2	2	1	2021-02-03	3	2	2	2		
88888-0023	Novel Coronavirus (WHO_nCoV)  - NGA-10151	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0023	2021-01-24	2	1	1	1	1	72	2	2	2	2021-01-03	2021-01-24	37	96	32	100	70	2	2	93	1	1	10	2															2	2	2																																																												1		1		1		1	1		1		1	1	1	1	1	1	1		1	1		1	1	1	1		1	1	1	1																																																																																																																																																																																																																																																																																																																													
88888-0021	Novel Coronavirus (WHO_nCoV)  - NGA-10151	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0021	2021-01-22	1	1	1	1	1	67	2	2	2	2021-01-15	2021-01-21													2	2	1	2	2	2	2	3	2	2	2	3	2	4	2	1	2	2		1	2	1	2	1	2	2	2	2	2	2	2	2	2	1	2	1	2	2	2	1	2	2	2	2	2	1	2	2	1	2			2	1	1	2	2	2	2	1	1	1	1	3	2		1	1	2	2	2	2	2	2	Azithromycin, levofloxacin	14.0	1	110	1	15370	1	130	1	1	3.5	1	164000	1	1	1	1	1	1	1		1	1		1	1	1	1	9.4	3	1	1	1	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0021	2021-01-30	37.2	97	30	139	87	2	3	9	84	2	1	2	2		2	2	2	1	2	1	2	2	1	2	3	2	1	2			2	1	2	2	2	2	2	1	1	2		1	3	2	4	2	2	2	2	2	2	15.4	1	101	2	18220	1	129	1	1	4.4	1	263000	1	1	1	1	1	1	1	1	1	1	1	1	1	9.0	3	1	1	1	Rocephine	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0021	2021-02-04	36.7	112	20	160	111	2	3	11	95	2	2	2	2	2	2	2	2	1	2	1	2	2	1	2	2		2	1	2			2	1	2	2	2	2	2	1	1	2	1	3	2	4	2	2	2	2	2	2	14.5	1	41	2	16910	1	128	1	1	3.8	1	185000	1	1	1	1	1	1	1	1	1	1	1	1	1	6.3	3	1	1	1	Levofloxacin																																																																										WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0021	1	3	1	3	1	2	3	2	3	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	2			1	Azithromycin, Ceftriaxone, Levofloxacin	2	2	2	2	2	1	5		1	1	12	3	2	4	1	4	2	2	2	2	2	4	2021-02-07		2	2	1	Clexane	
88888-0053	Novel Coronavirus (WHO_nCoV)  - NGA-10151	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0053	2021-03-01	1	1	1	1	1	76	2	2	2	2021-02-22	2021-03-01	36.3	112	24	186	97	2	3	76	2	1	10	2	2	1	1		2	2	2	3	2	2	2	2	2	4	2	1	2	4		1	2	1	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	2	2	2	2	2	1	2	2	1	2			2	1	2	2	2	2	2	1	1	1	1	3	2	4	2	2	2	2	2	2	2	2	Rocephine, Levofloxacin	11.8	1	268	2	18180	1	145	1	1	4.8	1		1	1	1	1	1	1	1		1	1		1	1	1	1	18.2	3	1	1	1	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0053	2021-03-03	39.7	112	28	152	78	2	3	7	65	2	1	1	1	2	2	2	2	2	2	1	2	2	2	2	2	2	1	2			2	1	2	2	2	2	2	1	2	1	2021-03-03	1	3	2	4	2	2	1	2	2	1		1		1		1		1	1		1		1	1	1	1	1	1	1	1	1	1	1	1	1		1	1	1	1	Rocephine, Levofloxacin																																																																																																																																																																	WHO_nCoV	Federal Medical Center, Asaba	Nigeria	88888-0053	2		1	2	1	2	2	2	2	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	2			1	Rocephine, levofloxacin	2	2	2	2	2	1		2021-03-03	1	1	2	3	2	4	1	1	2	2	2	1	2	4	2021-03-03		2	2	1	Clexane	
